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Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is
the only curative treatment modality for many patients affected by hematologic
malignancies. However, it can cause debilitating long-term effects. Understanding
the impact of alloHSCT on all aspects of the patients’ life is required for optimal
survivorship management.
Aim: To explore in-depth HSCT-survivors’ experiences and needs post-transplant.
Partners were included to provide further information on survivors’ needs and how care
could be improved in this area.
Methods: We conducted semi-structured face-to-face and phone interviews with
alloHSCT-survivors and their partners referred to a survivorship clinic in Germany.
Theoretical sampling was used to recruit participants. Data were analyzed using
framework analysis.
Results: Thirty-two survivors (consent rate: 100%, response rate: 100%) and eighteen
partners (consent rate: 84%, response rate: 72%) participated. Survivors were aged
between 25 and 68 years (Median: 48, IQR: 25.3) and partners were aged between
26 and 64 years (Median: 54, IQR: 16, SD: 12.8). The themes emerging from the data
involved survivors’ needs included (i) the diversity of long-term treatment side-effects;
and (ii) time post discharge as a dynamic process with individual peaks of burden.
Survivors and their partners also suggested strategies for mitigating these unmet needs,
i.e., (iii) transparent communication and patient empowerment; and (iv) improvement
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in continuity of care system and help with claiming social benefits as cornerstones of
optimal survivorship care.
Conclusion: To our knowledge, this is one of the first qualitative studies focused
on the views of German alloHSCT-survivors on the long-term effects of alloHSCT and
the first study integrating the view of their partners. Healthcare providers could better
support survivors with managing their symptoms and adhering to their prescribed care
by ensuring comprehensive, transparent communication that helps increase survivors’
understanding and involvement in their care. Further efforts should be made to provide
patient-centered, continuous survivorship care that involves additional support with
navigating the healthcare and social service system. Intervention studies are required
to test the effectiveness of the suggested strategies.
Keywords: allogeneic hematopoietic stem cells transplantation, survivorship, patients view, framework analysis,
qualitative research, GvHD
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (alloHSCT)
is the only curative treatment modality for many patients
affected by a number of hematological disorders, both malignant
and non-malignant, including high-risk leukemia, lymphoma,
myelodysplastic syndrome and myeloproliferative disorders (1–
3). Around 20,000 patients receive alloHSCT in Europe each
year with approximately half of them developing some form
of acute and/or chronic graft-vs.-host disease (GvHD) (4). In
2020, more than 4,000 patients were treated with alloHSCT in
Germany, receiving care in one of more than 60 specialized
treatment centers. The vast majority of these treatment centers
are part of university hospitals providing tertiary healthcare
to both inpatients and outpatients (4). AlloHSCT involves
chemotherapy and/or radiation therapy (conditioning), followed
by the infusion of hematopoietic stem cells. Various adverse
effects may appear from conditioning and particularly from
the transplantation itself, including transplant related organ
dysfunction, secondary malignancy, and serious infections.
Managing these multiple complications are quite challenging
for both physicians and survivors (5–7). A recent review of
observational and intervention research focused on the unmet
needs among patients with hematologic cancers and concluded
that HSCT is a risk factor for great unmet needs (8). Boyes et al.
found that patients with hematologic cancers also experience
higher levels of psychological morbidity including symptoms of
anxiety and depression, compared with patients diagnosed with
other common cancer types, such as breast or prostate cancer (9).
AlloHSCT can further cause a number of long-term effects
on survivors, including chronic GvHD (cGvHD) which affects
up to 50% of survivors (10). This immunological disorder can
impact on almost every organ system leading to a variety of
symptoms, such as skin sclerosis, dry eyes and inflammation
of the oral mucosa. Long-term toxicity may also impair
neurocognitive function, bone density among other symptoms
and thereby limit physical functioning and quality of live (10, 11).
Due to improvements in treatment modalities and decreasing
mortality rates following HSCT the number of survivors is
increasing (12–14). While many HSCT-survivors struggle with
self-management and adherence to their prescribed care (15)
little is known about survivors’ perspective on how long-term
effects of alloHSCT impact on their lives, and how healthcare
providers could better help them manage their symptoms and
care (16, 17). For example, Laidsaar-Powell et al. conducted a
recent review on adult cancer survivors and found that compared
to other common cancers with relatively high survival rates,
such as breast or prostate cancer, there is considerably little
evidence about the perceptions and experiences of survivors of
hematological cancers, particularly with regard to the long-term
effects of alloHSCT, such as cGvHD (18–20).
One of the crucial resources in coping with the long-term
sequelae of transplantation are resorting to support from partners
(21). Partners commonly help survivors recall information
delivered by their treating clinicians, provide guidance on
treatment decision making and support survivors with managing
their care and doing daily activities post discharge (22). Partners
can provide important additional information on survivors’
needs and wishes as they are often the most important part
of survivors’ social network and one of their main sources
of information, advice and support (22–24). Also, involving
survivors’ supportive others, are cornerstones of optimal patient-
centered care which has become the gold standard of care
delivery (25, 26). However, only few studies include data
provided by partners, and to our knowledge, none has focused
specifically on the long-term needs and wishes of alloHSCT-
survivors and also included their partners’ views in relationship
to survivors’ needs and care using a qualitative approach (27).
Most studies in this area investigate specific aspects of survivors’
and partners’ needs such as QoL, focus on partners’ own needs
or use quantitative methods to explore survivors’ and partners’
views (28).
Research is needed that examines the dynamics and
interrelation of survivors’ and their partners’ views, experiences
and needs related to optimal survivorship care following
alloHSCT (20). Qualitative research is particularly suited to
fill this gap as it provides valuable in-depth insights into
survivors’ perceptions of their care and thus enhances our
understanding of existing quantitative data on hematological
cancer survivors’ views (29). Conducting qualitative research can
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further help discover areas for improvement of care and inform
the development of interventions to help survivors better cope
with their symptoms (30, 31). Yet, only few qualitative studies
explored alloHSCT-survivors’ experiences post-transplant (19,
32–37), with many of them focusing on survivors of leukemia or
lymphoma (33). Also, there is still a lack of research on how care
in this area could be improved and, to our knowledge, very few
qualitative studies have focused on the views and perceptions of
European alloHSCT-survivors taking into account that findings
from other contexts may not be generalizable due to differences
in healthcare settings and services. We therefore performed
qualitative semi-structured interviews with German alloHSCT-
survivors and their partners to provide in-depth insights into
survivors’ views on how long-term effects of alloHSCT impact on
their lives, and how healthcare providers could better help them
manage their symptoms and care.
METHODS
Aims
This study explored in-depth the alloHSCT-survivors’
experiences and needs post-transplant. Partners were included
to provide further information on survivors’ needs and how care
could be improved in this area.
Study Design
Semi-structured face-to-face and phone interviews with
alloHSCT-survivors and their partners were conducted.
Participants
Survivors were eligible for this study if they (i) had received
alloHSCT between 1 and 5 years prior to recruitment, (ii) were
aged 18 years or older, (iii) were relapse-free after alloHSCT, (iv)
were German speaking, (v) and visited the Dept. of Hematology
of the University Hospital of Regensburg for routine follow-up
visits or second opinion at the GVHD clinic. Survivors were able
to participate regardless of their partner participation to ensure
that the views of single survivors were also included in this study.
The period of 1–5 years post alloHSCT was chosen as the first
year after alloHSCT is often characterized by acute complications
on treatment and thus not representative for long-term effects
and outcomes of alloHSCT-survivors. The 5-year limit has
been traditionally seen as a benchmark for cancer survivorship
indicating a time where cancer recurrence becomes less likely
(38–41). We only included relapse-free survivors as a relapse
often leads to a disruption of care which is then not focused on
survivorship but treatment of the underlying condition.
Partners were (i) identified by survivors as their partners,
(ii) aged 18 years or older (iii) German speaking, and (iv)
judged by clinic staff and the research team to be physically or
mentally capable of completing the interview and signing the
consent form.
Recruitment
Participants were recruited between November 2019 and June
2020. The attending physician identified all eligible patients based
on clinic records and asked for their consent to be contacted
by a member of the research team to schedule the interview.
Participants provided written informed consent by returning the
signed consent form. Survivors’ were asked whether they had
a partner and if so, whether their partner would be willing to
attend the interview. Survivors or partners were excluded after
three unsuccessful attempts to contact them or if they declined to
participate due to time constraints.
Theoretical sampling was conducted. Thus, initial consecutive
data collection from clinic lists and analysis informed later
recruitment to provide a maximum variation sample (42). Thus,
survivors from various age and gender groups, as well as
different socio-economic and disease-related backgrounds were
recruited to collect heterogeneous cases in order to compare and
progress the initial codes and categories (43). Ethical approval
was granted by the local research ethics committee (approval no.:
19-1306-101).
Data Collection
Participants could choose whether to conduct the interview
face-to-face or via phone to reduce research-related burden
on participants. Since the start of the COVID-19 pandemic,
all participants have opted for phone interviews. Interviews
were conducted by two interviewers (MP and AH), either one-
on-one or with survivors and partners interviewed together.
Consent was requested to record and transcribe the interviews.
Participants were advised that they had the possibility to stop
or to postpone the interview at any time. At the beginning
of each interview participants were asked to talk about the
impact the transplant had on their lives. This open stimulus
helped elicit the myriad of factors associated with the time
post-transplant. The narrative was followed by semi-structured
questions examining topic areas not raised about by participants
initially. Topic areas included physical and emotional well-
being and needs, information provided to survivors along the
care continuum, difficulties in daily routine and practical issues
(such as keeping the household or baying bills), impact on
relationships, and social and medical support provided by the
healthcare team (for detailed information in each topic area
please see the interview guide provided in Appendix 1). Partners
were prompted to add to the survivor’s narratives if they felt
they would like to elaborate on certain aspects further. The
interview guide was developed by the research team based
on a review of the literature and further interdisciplinary
discussion. It was also informed by the Supportive Care
Framework (44). The framework was developed as a tool for
cancer care professionals to help identify the type of support
cancer survivors may require and how to meet these needs
in healthcare service delivery (44). Employing a theoretical
framework helped summarize and integrate existing knowledge
on supportive care to provide guidance for research and clinical
practice specific to the experiences and needs of alloHSCT-
survivors (45).
Data Analysis
All interviews were transcribed verbatim. Data were analyzed
using the framework method which is a systematic approach for
examining commonalities and differences in qualitative research
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data (46). It allows to provide highly structured outputs by
summarizing descriptive and explanatory data and categorizing
this data into developed topics (46). At the beginning of the
analysis, the data were read intensively to identify generic terms
that were clustered into categories (46). This step is called
“open coding” and involves translated passages of the transcribed
interview into key messages, which are then grouped into
categories. The developed system of categories was discussed and
double-checked within the research team. Once the system of
categories (“the framework”) had been agreed on, the content
of all interviews was scanned to assign further data to the
framework (46). If additional topics repeatedly appeared, the
analytical framework was constantly revised and completed
until a final category-system was achieved (i.e., no additional
new information arising). Again, the system of categories was
discussed by the research team. This dynamic and iterative
categorization allowed for the analysis of data in a detailed
manner and enabled us to establish links between the categories.
The final output of the analysis was summarized in the form
of themes which were developed by interrogating the categories
through comparison within and between interviews in order
to form interpretive concepts that describe or explain certain
aspects of the data (47).
RESULTS
Thirty-two survivors and twenty-five partners were approached
(seven patients indicated that they were not in a relationship). All
survivors agreed to participate, and eighteen partners contributed
to the study (consent rate: 84%, response rate: 72%). Reasons for
declining study participation were time constraints (n = 5) or
lack of interest in this study (n= 2). Survivors were aged between
25 and 68 years (Median: 48; IQR: 25.3; SD: 14.1) and partners
were aged between 26 and 64 years (Median: 54; IQR: 16). The
median time since allogenic HSCT was 2.7 years (range: 1.2–5
years, IQR: 1.3, Tables 1, 2). Interviews lasted between 25 and
88min (Median: 50.4, IQR: 25.2).
The themes that emerged from the data of survivors and
partners were grouped around needs, i.e., (i) the diversity of long-
term treatment side-effects as a major challenge in alloHSCT
survivorship care; (ii) time post discharge as a dynamic process
with individual peaks of burden; and strategies for clinical
practice tomeet these needs, i.e., (iii) transparent communication
and support with patient empowerment; and (iv) continuity
in the care system and help with claiming social benefits as
cornerstones of optimal survivorship care. These themes are
described in detail below.
A summary of the themes and suggestions for how to improve
care can be found in Table 3.
Diversity of Long-Term Treatment
Side-Effects as a Major Challenge in
alloHSCT Survivorship Care
Survivors and partners reported great diversity of long-term side-
effects of alloHSCT and varying degrees of burden caused by
each side-effect of treatment. Given the complexity of GvHD
TABLE 1 | AlloHSCT survivors’ sociodemographic and disease
related characteristics.
Characteristics Survivors







Median Age in years (SD) 48.0 14.1
18–39 y 11 34%
40–59 y 11 34%
60+ y 10 31%
Material status
Married 21 66%
Stable Relationship 4 13%
Single/widowed 7 22%
Highest level of education
No university degree* 22 69%






Non-Adult Children 12 38%
Adult Children 8 25%
None 12 38%
Median Time post HSCT in years (SD) 2.5 1.1
1–2 y 8 25%
2–3 y 15 47 %
3–4 y 3 9%
4–5 y 6 19%
Diseases
Acute myeloid leukemia 9 28%
Acute lymphoblastic leukemia 7 22%
Non-Hodgkin Lymphoma 5 16%
Chronic myeloid leukemia 3 9%
Lymphoma 2 6%
Myeloproliferative disease 2 6%
Inborn immunodeficiency 2 6%
Others 2 6%





*Year 10 or lower, A levels.
they indicated that such care should ideally be provided by a
clinic or center that is specialized in this area. Survivors attending
specialized clinics felt that they received care that was more
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TABLE 2 | Partners’ sociodemographic characteristics.
Characteristics Survivors






Median Age in years (SD) 54.0 12.8
18–39 y 4 22%
40–59 y 9 50%
60+ y 4 22%
Highest level of education
No university degree* 12 67%







*Year 10 or lower, A levels.
TABLE 3 | Main themes and suggestions for clinical practice.
Issues mentioned Possible approaches
Diversity of long-term
treatment side-effects as a
major challenge in alloHSCT
survivorship care
Time post discharge as a
dynamic process with
individual peaks of burden
1. Increased education of survivors and
support persons about side-effects
of alloHSCT prior to transplant and
guidance on how to identify and
communicate concerns and wishes
2. Continuing medical education on how
to provide specialized care post-
transplant
3. Provision of individually tailored
survivorship care plans and easy
access to multidisciplinary care teams
Transparent communication
and support with patient
empowerment
1. Healthcare provider training in patient-
centered communication
2. Fostering patient self-management
through involvement of liaison nurses
3. Provision of further publicly available
information about treatment centers
4. Access to revalidation programs
(e.g., as online course to reduce risk
of infection)
Continuity in the care
system and help with
claiming social benefits as
cornerstones of optimal
survivorship care
1. Patient navigators and bridging
nurses to coordinate continuous,
individually tailored care, help
navigate social support systems and
maintain and strengthen
communication and collaboration
between all member of the
multidisciplinary care teams
tailored to their individual needs and circumstances. The most
frequently mentioned complication survivors struggled with was
cutaneous cGvHD causing skin erythema, dryness often resulting
in lasting visible transformations of different parts of the skin.
A number of survivors reported having “typical GvHD spots”
(female survivor, 57 years, two and a half years post alloHSCT)
and described a great degree of suffering from a very dry and
sometimes itchy feeling, getting worse during sun exposure.
Some participants reported that the mucous membranes of the
intimate area were affected by the GvHD causing pain during
sexual intercourse.
“It doesn’t hurt, but it is so visible – skin looks like parchment and
it dries out relatively quickly. [...] and then I have these spots. This
was the first thing that we noticed.” (male survivor, 36 years, three
years post alloHSCT)
“My mucous membrane was quite affected. It was as if my
vagina was glued together.” (female survivor 47 years, four years
post alloHSCT)
Even though cutaneous cGvHD is a common problem, the
perceived burden caused by this complication varied significantly
between survivors.Women often reported beingmore concerned
about visible transformations of their body than men and
reported “not feeling attractive” anymore (female survivor, 46
years, 2 years post alloHSCT). Compared to male survivors,
women also seemed to struggle more with the side-effects of
long-term corticosteroids treatment, such as weight gain or
facial oedema.
“My skin is covered with brown spots. They are scars, they won’t go
away anymore. It is particularly bad when that happens on the neck
and in the face. [. . . ] Especially for me as a woman it is not so easy
to come to terms with that.” (female survivor, 57 years, two and a
half years post alloHSCT)
You feel bad anyway as a cancer patient, without hair and so on.
And after the transplant your whole appearance changed. And then
you don’t want to take cortisone in huge doses because you gain
20 kilos. [. . . ] It is the outward appearance especially for women.
You would like to be like you were before [=alloHSCT]. (female
survivor, 46 years, two years post alloHSCT)
Even years after receiving alloHSCT, most survivors perceived a
reduced level of general fitness and self-effectiveness compared to
the time prior to the transplant. Some described this as a reduced
capacity to deal with problems of daily life or to do daily activities,
such as housekeeping or paying bills. Most reported lacking
physical strength, suffering from chronic fatigue and reduced
cognitive function. Thus, a significant part of survivors found it
hard to concentrate on a task for a longer period of time. They
also struggled with deciding what activities they are capable of
doing and what would be too much for them. This often resulted
in having to cancel appointments on a short notice and taking
numerous breaks during the day. Partners emphasized this loss
of fitness and highlighted survivors’ need to take regular breaks,
e.g., in the form of frequent and long naps during the day.
“I feel a complete lack of energy. When I have to get up the stairs,
I feel like I have been climbing Mount Everest.” (male survivor, 42
years, one and a half years post alloHSCT)
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“For me the problem was exhaustion, tiredness. [. . . ] I was
unsure how to handle that lack of energy and strength.” (female
survivor, 51 years, two years post alloHSCT)
“I realize that my diary fills up quickly and then afterwards I
have to cancel appointments because I simply don’t have enough
energy. And then I have to make sure that I don’t have an
appointment every day, let alone two in a day, that is much too
overwhelming for me.” (female survivor, 57 years, two and a half
years post alloHSCT)
“He sleeps a lot - a lot!” (female partner, 65 years)
The majority of survivors who did not suffer from a significant
change of their outer appearance noticed a discordance between
how their health status was perceived by others and their own
experience. This is due to the fact, that many symptoms they face,
such as fatigue, reduced fitness-levels or mental stress were not
visible from the outside. Survivors often reported being judged
by others as healthy although they felt physically and emotionally
vulnerable. This made it difficult for a number of survivors to
explain their supportive others, such as partners, relatives, friends
or work colleagues, how they felt and what they struggled with.
Some partners added that the survivors they cared were thus
often reluctant to talk to others about their feelings and well-
being as they did not wish to have to explain their disease and
symptoms. However, they needed to share their thoughts and
feelings with someone. In most cases this was their partner who
was already familiar with their situation and did not need further
explanation of their diagnosis, symptoms or treatment.
“From the outside you seem healthy, as the acute phase has
been over for some time. And the people around you they don’t
really recognize and understand that there are the negative long-
term effects (=of alloHSCT).” (female survivor, 44 years, two years
post alloHSCT)
“Well, you did have the need to talk. I remember last Christmas
when you really talked about all of this quite extensively (=your
disease and the side-effects of treatment). Do you remember?”
(female partner, 65 years)
Time Post Discharge as a Dynamic
Process With Individual Peaks of Burden
Survivors’ care experience after being discharged from hospital
was often seen as a dynamic process where individual survivors
experienced various peaks of burden at different stages of the
care trajectory, i.e., times that were perceived as particularly
challenging, both physically and emotionally. A significant part
of participants reported that these peaks occurred at the time
of cancer diagnosis, but also at discharge. This was because
survivors felt that leaving the perceived safety provided by the
hospital system and arriving back home after receiving alloHSCT
fueled their fear of doing something wrong when managing their
symptoms and care. Most survivors also experienced a great
degree of burden and distress caused by the intermittent nature
and exacerbation cGvHD and lack of response to therapy. Almost
all survivors also suffered from having to isolate themselves to
reduce the risk of infections. Not being able to leave their homes
and being dependent on partners and other family members was
seen as particularly burdensome.
“On the day of discharge, I was at completely down. I was really
devastated. My first reaction on the day of discharge, when my
wife picked me up, was: If that [=the cancer] comes back, I
won’t go through this again.” (male survivor, 62 years, five years
post alloHSCT)
“You don’t get any support. You are discharged. Then you are
at home. You get your pills and then the nurses and clinicians
say: ‘If anything happens, please ring us and you can come in
straight away, but that doesn’t help you very much at home.”’ (male
survivor, 62 years, one and a half years post alloHSCT)
“I was so used to being among people, always in company. And
then me being at home onmy own [. . . ] that was the worst.” (female
survivor, 47 years, four years post alloHSCT)
Partners highlighted survivors’ suffering when coming home,
particularly due to their dependence on partners’ care. They
reported helping survivors through this difficult time, especially
by providing support with coping emotionally with their
disease and treatment, helping with practical problems, such as
attending clinics, paying bills or keeping the household, and
supporting survivors understand the information provided by
their clinicians and becoming involved in decisions regarding
their care.
“I thought: How can we cope? Because he [=the survivor she
cared for] practically had to be nursed when he came home. And I
had a job to go to. One of us had to keep up a job.” (female partner,
54 years)
“I always thought we would overcome this. Of course, sometimes
you struggle. But sometimes you feel joy. (. . . ) We learned to live
with the disease. Well, we always have to work on it and learn to be
tolerant (. . . )” (female partner, 65 years)
“It’s crazy what this does to you (=the alloHSCT). I just
remember when he came home (=from hospital), he was done. He
could hardly walk. I had to shower him, clean the whole house,
wash the curtains, change the bed sheets every day. It was extreme.”
(female partner, 49 years)
Due to their reduced level of physical and cognitive function a
significant part of survivors and their partners were forced to
reduce their workload, work part-time or quit work completely.
Younger survivors often had to take a break from university
or vocational training resulting in a great degree distress and
insecurity regarding the future. Apart from the financial struggle,
having a job meant having a purpose in life for most survivors
as they wished to perceive themselves as valuable members of
the society. Most survivors who lost their job felt useless, socially
isolated or bored.
“We (=partner and survivor as independent entrepreneurs)
have limited our working hours so that I can look after my wife.”
(male partner, 63 years)
“I cannot go to work anymore. It is no longer possible. It is very
hard for me to understand that.” (female survivor, 57 years, two
and a half years post alloHSCT)
“My money has vanished altogether, about 1000 euros per
month gone. My husband took six months off. Honestly, I have to
say: all our savings were completely used up.” (female survivor, 47
years, four years post alloHSCT)
Frontiers in Public Health | www.frontiersin.org 6 July 2021 | Volume 9 | Article 687675
Parisek et al. GVHD Impacts Life
“Every time I went to the letter box I felt anxious because there
were more bills [. . . ] I didn’t want to make that experience, no one
would.” (female partner, 65 years)
A number of survivors suffered from having to take high doses of
numerous different types of drugs in order to manage the side-
effects of alloHSCT. They also struggled with the lengthy and
frequent check-up visits at the clinic. Failed attempts to reduce
medication and stagnation in rehabilitation were perceived to be
particularly challenging. Some survivors reported that cGvHD
and trying to manage its symptoms completely took over
their lives, reducing their hope that things might improve and
impacting their drive to make plans for the future.
“[M]y systemic immune suppression has not changed. Every
single tapering strategy has failed. I cannot reduce the high level
of suppression. That has left me emotionally drained.” (female
survivor, 44 years, two years post alloHSCT)
“[W]hen I take these tablets, 26 per day, when I take half of
them in the morning, I feel so sick. I just want to go back to bed.
Because all the energy that my body has left is used up in the process
of metabolizing the drugs.” (female survivor, 51 years, one and a
half years post alloHSCT)
“This GvHD determines my life. That’s it. To some extent I have
lost hope that I will ever be able to reduce all this medication. ”
(female survivor, 57 years, two and a half years post alloHSCT)
Transparent Communication and Support
With Patient Empowerment
Most survivors indicated that their treating clinicians had
told them that receiving alloHSCT would be tough and time-
consuming. However, they were nevertheless surprised and
sometimes even shocked by the extent and intensity of the
treatment side-effects and by how much they would affect their
lives. A significant part of study participants only realized post-
transplant that alloHSCT would not provide the quick cure they
wished for, but that the recovery period would be a crucial
and burdensome part of their care trajectory. Partners also
highlighted the feeling of not being prepared for the impact the
transplant had on the survivors they cared for, particularly the
changes on personality, the changes related to their bodies and
the cognitive difficulties they had to cope with post-transplant.
“And I have to admit, I did not expect the treatment
complications.” (female survivor, 57 years, two and a half years
post alloHSCT)
“And that was a totally new experience to acknowledge or to
learn to acknowledge that you are not cured but that the process
of healing was continuing and that the time after the transplant
was a very important time.” (male survivor, 62 years, two years
post alloHSCT)
“From one day to the next I thought there is another man lying
in the room. (. . . ) His head and neck were swollen. I couldn’t believe
that it was him. It was a shock.” (female partner, 62 years)
Survivors in this study varied greatly in terms of their preferences
for the type and the amount of information they wished to
receive. Some wanted their clinicians to provide all available
details of their diagnosis, prognosis and treatment options, others
preferred to only receive general information that helped them
understand what happened to them. These survivors felt that too
much information would scare them. All survivors appreciated
if information was given to them in lay-language and in a
structured manner to ensure survivors and their partners would
not be overwhelmed by the amount of information they received.
“As a layperson you cannot understand that jargon when you
get confronted with it. There should be a training program for
clinicians to help them to explain something in a way that the
patient can understand.” (female partner, 65 years)
“You get so much information that you cannot really
understand what has just happened. The first information came like
a landslide.” (male survivor, 68years, two years post alloHSCT)
“It’s a very personal thing [=information needs and
preferences]. Everybody is different. Clearly there are things I
need to know. But there are also things when I think, just leave
them. I don’t want to know. Yes, I would worry too much.” (female
survivor, 68 years, two years post alloHSCT)
Some survivors also highlighted the importance of their clinician
being mindful about how they provide information and how
this is received by survivors and partners. A number of
survivors reported that clinicians thought out loud what they saw
when examining them or reading their test results. Clinicians
often said what they concluded from these examinations or
test results without actually addressing survivors directly or
filtering the information in order to make it understandable
and less anxiety provoking for not medically trained people.
Consequently, survivors immediately thought that something
was wrong causing them a great degree of distress that could have
been prevented by more careful means of communication.
“The ultrasound image showed up something on my thyroid.
And then they [=the treating clinician] say to you: ‘Well, we’ll
definitely have to investigate that. You were getting radiation
therapy and some tumors can come back.’ And my reaction was:
danger, danger, danger!” (female survivor, 57 years, two and a half
years post alloHSCT)
Many survivors reported not adhering to their prescribed care,
e.g., their medication or isolation, as they were overwhelmed
by the myriad of instructions and limitations they had to
integrate into their daily lives. Clarifying the reasons for these
limitations, prioritizing some over others and providing practical
recommendations for how to put the instructions into practice
were perceived important aspects to help survivors increase
adherence to their prescribed care. Survivors reported that
liaison nurses provided a lot of support in this area, particularly
by showing them how to administer medication, answering
questions regarding how to reduce the risk of infection or giving
advice on nutrition. These liaison nurses involved a group of
specially trained nurses who provide tailored follow-up care.
The liaison nurses also helped survivors by educating partners
on the recommended care, as they were the ones who often
implemented the provided guidelines, especially in the period
immediately after discharge.
Frontiers in Public Health | www.frontiersin.org 7 July 2021 | Volume 9 | Article 687675
Parisek et al. GVHD Impacts Life
“Maybe not just what you shouldn’t do, but also an explanation
why [=certain things should be done] would be good.” (female
survivor, 51 years, two years post alloHSCT)
“I was looking for hours to find the right sunscreen and to check
all the products, to understand the pros and cons and check the
ingredients for those I should stay away from. Maybe you could
improve that a bit by making sure you have a product to start with
and then you can go and look for others to continue with.” (female
survivor, 51 years, two years post alloHSCT)
“If we had known that you can eat pealed raw veggies, we would
have had a carrot salad or something like that a long time ago. But
we avoid all of this, just to be safe.” (female partner, 31 years)
Some survivors wished for more information about alternative
medicine and how it could be used to reduce drug-interactions.
Others would have appreciated further details on the clinic they
attended, including more comprehensive readily available and
trustworthy information on the experience and qualifications of
the clinicians who treated them. This was because most survivors
felt that centers varied greatly by the quality of care that was
provided, with some not being perceived to be up-to-date with
current clinical guidelines and recommendations on optimal
patient-centered communication and care prior, during and post
alloHSCT. Some survivors wished for clear, publicly available
information on each healthcare center, for instance regarding
the number of transplants administered per year and clinicians’
experiences with treating different hematological conditions.
“I believe that many patients would like to use alternative ways
or means in order to avoid using chemical drugs. And they could do
with more support on that.” (female survivor, 51 years, two years
post alloHSCT)
“I think it is a great problem to find a clinic that doesn’t just
do a sufficient number of transplants but also has experience with
very different types of disease because that ensures that follow-up
care will work well. [. . . ] But that information doesn’t exist. The
public relations department [=of each clinic] writes nice adverts
on how great everything is and all the things they do at the clinic
but quite often there is a lack of information on things like: How
many allogenic HSCTs do they do? How many autologous per year?
I don’t know how to improve this but maybe you have to force clinics
to communicate in a more transparent matter. Some people may
attend the clinic closest to their homes although they won’t receive
the best care there.” (female survivor, 57 years, two and a half years
post alloHSCT)
Easy access to appropriate support with physical activity was
seen as another facilitator for optimal survivorship care. Most
survivors found it important to increase their physical fitness
and felt this would help them cope emotionally with their
new situation. They reported that physical activity allowed
them to increase their self-confidence, optimism and self-
effectiveness, and receive a welcomed distraction and timeout
from daily routines and concerns. Despite this, most struggled
with attending open fitness centers or sports classes, since they
were concerned with the risk of infection and of potentially
crowded exercise areas. Some also felt that open fitness centers
may not be sufficiently tailored to their physical and mental
well-being and may thus expose them to exhaustion. They
wished for courses and fitness plans tailored specifically to their
specific needs after alloHSCT and guided by a trained instructor.
Survivors also indicated that such programs should be better
communicated in order to raise awareness among survivors and
treating clinicians.
“Sport has always been good for me because doing sports also
provides psychological support.” (female survivor, 49 years, two
years post alloHSCT)
“When I got home from hospital, I had no energy. But I needed
to get out and (walk) a little bit further every day. I could draw a
lot of energy from that. I always say, I am walking away from my
illness.” (female survivor,64 years, three years post alloHSCT)
“I cancelled my sports class because I didn’t go there anymore.
I can’t do any exercises on the floor anymore due to my hip and
back. And the floor is contaminated, and I don’t want that either.
Nothing is being done here in X [=city where the survivor lives] . . .
I mean that they should try to offer sports classes that are suited for
HSCT-survivors.” (female survivor, 57 years, two and a half years
post alloHSCT)
Continuity of Care and Help With Claiming
Social Benefits
Being discharged from hospital was particularly challenging for
survivors who lived far away from the clinic they were treated
at. In case of emergency, they often attended an emergency
department close to their homes where they did not feel their
disease and concerns were treated adequately. Some felt that this
was because of smaller clinics’ lack of experience with providing
specialized care to alloHSCT-survivors. A number of partners
reported not having received adequate care when they had to take
their partner to the nearest emergency department.
“And there is always the fear something could happen. And what
makes it worse for us: we live 138 km away from X [=place of the
clinic they attended]. [. . . ] What I found most devastating was that
every time I had to take my husband to the emergency department
[. . . ] the people there didn’t take us seriously and sent us to the
waiting area. And I had to get up and fight for my husband to
be treated immediately. Those were the worst moments.” (female
partner, 59 years)
A number of participants reported a lack of communication
between their treating specialists, general practitioners (GPs)
and the emergency departments they attended. GPs and local
emergency departments were often not aware of the special
needs of alloHSCT-survivors resulting in survivors and their
partners having to close the gap of communication in order to
receive appropriate care. Survivors and partners in our study
wished for better information exchange between all members
of their care team, including primary, secondary and tertiary
care clinicians. They suggested continuing education for GPs
as well as better documentation and communication of the
details of each survivor’s care trajectory. Also, survivors noted the
importance often having the same clinician looking after them
during their follow-up check-ups. This allowed them to build
a doctor-patient-relationship which is based on mutual trust
and helped survivors gain confidence in their prescribed care.
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Such a doctor-patient-relationship was also seen as important
condition for survivors feeling confident to talk about openly
their individual problems and wishes.
“Involving the patient’s GP [=is important]. They should set
aside an hour or two between the GP and the specialist. The GP
is the extended arm [=of the specialist], aren’t they? This would not
cost a lot [. . . ] that they know exactly what they are doing.” (male
partner, 48 years)
“Every time I build a relationship with a doctor they leave soon
after. It is really annoying. Because you always talk a bit about
yourself. First, the doctor is a stranger to you, then, during the
second visit, you start to get to know them, and again during the
third visit, and when you want to meet them for the fourth time
they are gone.” (female survivor, 57 years, two and a half years
post alloHSCT)
Survivors and partners in our study wished for more tailored
help with claiming social benefits and seeking further practical
support. They suggested introducing a temporary care level for
the times they struggled most post-transplant.1 Others reported
an unmet need for improved access to paid housekeepers and
additional sick leave for partners. A significant part of study
participants suggested that clinics provide a dedicated social
worker who is familiar with claiming social benefits and can thus
support each individual survivor and their partner. They noted
that it would be important to have such support during and
post discharge as help with claiming social benefits often stopped
once survivors left the hospital. As soon as they were back at
home, they often felt left alone with having to communicate
with different authorities and deal with various issues related to
their health and pension insurances. Given that some clinics did
not directly bill their insurers, a number of survivors found it
particularly time-consuming and burdensome having to forward
each and every treatment bill to their health insurer themselves.
“It would be really good if there would be a temporary care level
for the first six months, so that someone can drop in at your home
once a day.” (female partner, 54 years)
“What really annoys me was the letter from the pension
insurance. I think my blood pressure went up to 200 [. . . ] I had to
get my hips done and then they said: ‘Well, you have two new hips,
now you can work six hours a day and more.’ And then I thought:
Ok, how should I do that? I cannot stand for a long period of time,
I cannot sit. So, it really doesn’t work.” (female survivor, 57 years,
two and a half years post alloHSCT)
“Starting from the pension insurance on to the health insurers,
to the benefit agency, and so on. It was an odyssey, it really was.
It is unnecessarily difficult. It should be made easier. And I really
believe that the people who claim something really need it.” (female
partner, 65 years)
“That [=applying for pension and to receive disability
allowance] was a mental strain which I couldn’t stand any longer
in the end. Finally, I said to myself I don’t care anymore. I
don’t want to go on anymore. I do what they say even if I
1In Germany, the benefits of each person’s long-term health insurance cover
are provided in different stages which are also referred to as “levels of care.”
These levels of care are based on the severity of each person’s condition and help
categorize and classify the health insurance claims made.
have financial disadvantages. I don’t have any strength anymore.”
(female survivor, 64 years, three years post alloHSCT)
“Many hospitals don’t deal with the health insurances directly,
they simply don’t want to. That is then left to us. I have to pass
it on to the right people. [. . . ] I have put the money into a separate
account, tens of thousands of euros which I transfer into the account
and then I wait that the health insurer reimburses me for the
bills.”(female survivor, 64 years, four years post alloHSCT)
Survivors treated by liaison nurses reported that their team
helped them through this difficult time by offering care and
support with questions or concerns they had. The liaison
nurses fostered continuous care by providing survivors and
their partners with a list of healthcare providers they could
contact if they needed help with social support or managing their
care at home. Liaison nurses were also seen as a facilitator for
multidisciplinary care involving primary, secondary and tertiary
healthcare services and maintaining communication between
different members of survivors healthcare team. Survivors and
partners who received this type of care greatly appreciated the
continuing and tailored support.
“And there is this - and I really have to praise it - this wonderful
system of building a bridge between hospital care and care at home.
There is someone who takes the time to tell us what to look out for
at home.” (male survivor, 62years, two years post alloHSCT)
“You always have the feeling that you can call the team of the
liaison nurses if you need to.” (female survivor, 68 years, two and a
half years post alloHSCT)
“You just feel well looked after within this system of liaison
nurses.” (female survivor, 46 years, two years post alloHSCT)
DISCUSSION
Our report builds on existing evidence (19, 36, 37) and highlights
the experiences and needs of hematological cancer survivors
including their partners following alloHSCT in a European
context of care. Survivors commonly reported the negative
impact of late effects and GVHD on their well-being across
different stages of survivorship. Notably, survivors also provided
new insight into the difficulties associated with accessing
specialized care, being empowered to self-manage their condition
and care as well as accessing social benefits they were entitled to.
Our findings provide new insights into an understudied area of
research and highlight the cornerstones of optimal survivorship
care post alloHSCT.
Many survivors and partners see the survivorship trajectory as
“dynamic process” with individual peaks of burden, a diversity of
long-term treatment side-effects and a clear need for transparent
communication (5, 18, 33). These peaks of burden did not
only occur at diagnosis but also at discharge requiring intense
psychosocial follow-up care involving (peer) support groups
and patient’s advocacy groups. Survivors felt that leaving the
perceived safety provided by the hospital system and arriving
back home after alloHSCT fueled their fear of doing something
wrong when managing their symptoms and care at home. Many
alloHSCT-survivors in our study struggled with the heightened
risk of infection, fatigue, limited fitness and neurocognitive
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decline and were reluctant to share their thoughts and concerns
with others than their partners as reported by previous studies
(14, 48, 49). They did not feel adequately prepared for this
transition from acute to chronic disease and struggled with
the disruption this caused in their personal life plans and
goals. They reported that peaks of burden occurred during
exacerbation cGvHD and lack of response to therapy. This is in
line with a previous study of Jim et al. describing the intermittent
nature of cGvHD as a source of burden and distress and
highlighting the potential benefit of patient education materials
to increase knowledge and self-efficacy in dealing with side-
effects of alloHSCT (50). It may be helpful to provide further
education of survivors and support persons about the side-effects
of alloHSCT prior to transplant and deliver guidance on how to
identify and communicate their concerns and wishes, so that they
can be addressed in a timely manner.
A model of care found particularly helpful by our study
participants is the system of liaison nurse, provided in some of
the clinics participants attended. This system involves specialized
nurses providing individually tailored advice on alloHSCT-
survivors’ supportive care post discharge, including constant
low threshold counseling on survivorship issues during the
recovery process post alloHSCT. A number of studies suggest
that involving liaison nurses can improve the continuity of care
and patient outcomes (51, 52). One of the key elements of
involving liaison nurses is that counseling already starts before
alloHSCT to help build a solid and continuing relationship before
further medical interventions are required. The need for such
models of care to help manage alloHSCT-survivors cope with
their symptoms and care has been highlighted previously (36, 53).
However, more intervention studies are required to examine the
effects of such models of care in alloHSCT-survivors and their
partners. Future research should also explore which elements of
tailored care planning work best in different settings and examine
barriers and facilitators to their implementation into routine care.
Taken together, our results indicate that care for alloHSCT-
survivors does not allow a “one-fits-all”-strategy but requires
healthcare service delivery that is tailored to the individual needs
and circumstances of each survivor. Tailored care post alloHSCT
has been shown to increase survivors’ capacity to self-manage
their care and even avoid loss to follow-up (54). McConnell et al.
examined different subgroups of cancer survivors highlighting
that tailored care planning is a key element in increasing survival,
treatment success and patient satisfaction levels (55). Wagner
et al. also emphasized the importance of tailored care planning
to support survivors’ self-management and help them and their
supportive others cope with chronic illness (56). Tailored care
planning can further enhance health-related quality of life,
reduce depression and reduce healthcare costs related to visits
to emergency departments (57, 58). It has also been suggested
that compared to usual care individualized care plans can lower
distress scores and improve the mental domain of QoL among
HSCT-survivors 1–5 years post-transplant (59). Despite this, the
use of tailored care planning is still relatively low in European
countries, with most studies conducted in the areas of chronic
obstructive pulmonary disease (COPD) and diabetes patients
(60, 61).
Participants in our study also indicated the need for continuity
of care after leaving the hospital. As also shown by others,
we noted that frequent changes of treating clinicians was
seen problematic as patients struggled with building trust
in their clinician and create profound relationships (62).
They wished for better interdisciplinary documentation and
communication, for instance through multidisciplinary teams.
Another way of improving collaboration between clinicians
from different disciplines and healthcare services might be
the use of electronic tools, such as electronic health records.
A number of studies in other settings suggest that this can
improve quality, safety and continuity of care as well as
interprofessional communication through quicker and easier
access to medical data allowing more efficient and patient-
centered care (63–65). Better interdisciplinary documentation
and communication may be particularly important when trying
to improve care for alloHSCT-survivors provided by local
emergency departments and GPs, who are often not familiar with
the special needs of alloHSCT-survivors and the requirements for
optimal care post-transplant.
Support in gaining social benefits was seen as further
facilitator for optimal alloHSCT-survivorship care given that
many survivors did not know what they were entitled to
and often felt overwhelmed and frustrated when trying to
obtain social benefits. Our data suggest challenges in claiming
social security benefits for orphan diseases, such as cGvHD,
caused by numerous problems. These include difficulties with
understanding the benefits survivors are entitled to, finding the
responsible authority and contact person and submitting correct
applications. Participants need professionals familiar with legal
provisions and practical aspects of social support to provide
them with timely information, e.g., prior to the transplant. This
could involve patient navigators who help survivors with taking-
up or returning to employment or complete their education
(66). Such navigators would be familiar with the situation of
each survivor and coordinate their healthcare support. They
could help engage survivors in proactive roles in their care
management, facilitate transition from hospital to community
care and improve communication between the members of
their treatment team (66). Employing patient navigators to help
alloHSCT-survivors and their informal caregivers access care and
further social support mechanisms could also improve adherence
to their prescribed care (66, 67). A recent study of Berezowska
et al. found that patient navigation can increase satisfaction
with care among survivors and healthcare professionals, improve
survivors’ self-efficiency and reduce distress (68). In some
settings, bridging clinics already take on some of these tasks
and help patients claim social benefits. However, there may be a
need support liaison nurses by providing patient navigators who
are trained more specifically for this purpose. Digital solutions
could also be used to support liaison nurses. For instance, Maher
et al. developed a HSCT-specific health IT tool called BMT-
Roadmap, that promotes survivor education and involvement
during hospitalization (69). A BMT Roadmap 2 for the outpatient
setting is currently being considered (70) and could also be used
to help survivors claim social benefits. Further attempts to use
eHealth to improve care post-transplant highlight the enormous
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potential of eHealth in promoting interdisciplinary collaboration
and patients’ satisfaction (71, 72). However, more research is
needed to validate such interventions (68).
Our data further suggest that survivors’ emotional and
mental well-being, their satisfaction with and adherence to
care could be improved by specific and continuing training
for clinicians on patient-centered communication, for instance
on more careful communication on how to deliver test
results. Survivors in our study reported that clinicians often
delivered test results accompanied by their first thoughts on
the interpretation and potential implications of these results.
This often caused survivors to assume the “worst case” scenario
resulting in substantial anxiety and distress (73, 74). Participants
also mentioned the importance of understanding the reasons
for their prescribed care post-transplant, including detailed
information on their medication and infection prevention
measures. Survivors highlighted that this would help increase
their feeling of being actively involved in their care and increase
their adherence to their prescribed care. This is in line with
several studies in other chronic settings which suggesting that
survivors are more likely to be able to self-manage and adhere
to their care instructions if they are empowered to do so by
being told why specific care instructions were given and what
important role they play in their own recovery and survivorship
care (75–77). Tailored communication trainings could also help
clinicians enable and empower their patients and informal
caregivers (78). This may be particularly important if patients
or their support persons as informal caregivers feel they have
misunderstood certain aspects of their diagnosis, prognosis or
care but do not dare to mention this. Training in patient-
centered communication could help assist patients and informal
caregivers with expressing these unmet information needs, so
that clinicians can address them.
Participants in our study also indicated that communication
could also be improved by providing publicly available
information on center characteristics such as the number
of transplants administered per year, the number of
different diseases types treated and how survivorship care
is being delivered at each clinic. Similar efforts have been
made in other areas of medicine suggesting that such
information allows survivors to make informed decisions
regarding their care (79). This has been show to improve
patient trust in their clinicians and may also increase
healthcare providers’ commitment to improve the quality
of care (80, 81).
A number of outcomes, such as adherence to the prescribed
care, could also be increased by involving the triad of clinician,
survivor and their informal caregiver (82). A number of studies
suggested that involving survivors’ supportive network is a
key element of optimal patient-centered care (83, 84). Our
data confirmed this as partners played an important role in
helping survivors cope with the long-term effects of alloHSCT.
Partners and other members of survivors’ supportive network
often provide one of the most important sources of information
and advice for survivors, and can play an important role in
treatment decision making (22). They have been found to help
improve a number of survivors’ outcomes, including mental
health and long-term survival (85–88). Informal caregivers
can further provide valuable additional information on aspects
of care survivors struggle with and how to overcome them
(86). More research is required that involves the views
of survivors’ supportive others on how to improve their
care (21).
Finally, many survivors mentioned physical activity as an asset
to cope with the long-term effects of alloHSCT, increase their self-
confidence, optimism and self-effectiveness, and as a welcomed
distraction and timeout from daily routines and concerns. This is
in line with previous studies suggesting that physical activity can
improve survivors’ outcomes, such as decreased hospitalization
and better physical health (89, 90). Wiskemann et al. found a
positive correlation between non-relapse mortality and physical
activity (91). However, many survivors in or study struggled
with attending general fitness classes given a perceived risk
of infection. In light of these findings and given the current
COVID-19 pandemic online exercise classes may help provide
survivors with an opportunity to stay physically active. However,
further research is required that investigates how to design and
implement physical activity classes that are tailored to the special
needs and circumstances of alloHSCT-survivors.
LIMITATIONS
Our results do not intend to be numerically representative.
We employed theoretical sampling which is typically used in
qualitative work and aligns with the aims of this study to provide
fresh in-depth insights into survivors’ needs and experiences,
which is a recognized component of optimal care (92). Our data
also make suggestions for how to improve care in this area which
can guide clinical practice and resource allocation. However, due
to differences in healthcare services and systems our findingsmay
not be generalizable to other settings. Our findings highlight that
partners may provide valuable information on survivors’ needs
and experiences by complementing their narratives and raising
topics not initially raised by survivors. Participating survivors
did not feel intimated by the presence of their partners but
appreciated sharing their thoughts and experiences with the
support of their partners. This is in line with previous studies
highlighting that interviewing individuals and their partners
together could generate richer data than interviewing them
separately due to the interaction between the interviewees leading
to a more holistic presentation of the studied phenomena (93–
95). However, it was not possible to include partners for all of our
interviewees due to difficulties with recruitment, mostly due to a
lack of time. Theoretical sample ensured the representativeness
of the included participants in terms of age, gender, and
socioeconomic status. Despite this, a significant percentage
of survivors were married and attained year 10 or lower of
education which could potentially limit the generalizability of
the results. Also, we involved a limited number of centers and
participants received alloHSCT at different centers and thus
received different transplant-related education, and different
support once discharged. This may affect the unmet needs found.
Finally, there may have been recall bias since participants were
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asked to comment on HSCT which was a number of years ago
for some.
CONCLUSION
This qualitative study provides novel insights into alloHSCT-
survivors’ experiences and needs post-transplant. It also includes
partners’ views with the aim to add further information on
survivors’ needs and how care in this area could be improved.
Our results suggest that the time post discharge is particularly
challenging for most survivors who also often struggle with
neurocognitive decline and the need to reduce their workload or
quit work altogether during long-term survivorship. Survivors in
our study wished for further efforts to ensure patient-centered,
multidisciplinary, holistic, continuous survivorship care that
is tailored to their specific needs. Additional support with
navigating the healthcare and social service system as well as help
with understanding and participating in their care could increase
adherence to care, self-effectiveness and physical and mental
well-being. This would involve improvement in communication
and education along the whole transplant continuum, so
survivors can understand what they are dealing with and what
resources they may be entitled. This may be achieved by
having specialized patient navigators and liaison nurses. Finally,
intervention studies are required to test the effectiveness of the
suggested strategies and, if found to be effective, investigate
how these strategies could be best implemented into routine
cancer care.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by ethics committee of the University of Regensburg.
The patients/participants provided their written informed
consent to participate in this study.
AUTHOR CONTRIBUTIONS
MP: conducted the interviews and wrote the manuscript.
JL: supervised the project. EH: supervised the project and
commented on the manuscript. AB: added to the discussion of
the data. DWe: recruited patients. ME: edited the manuscript.
DWo: initiated the project and supervised the project.
AH: initiated the project, performed the interviews, and
wrote the manuscript. HS: contributed to the discussion and
manuscript. All authors contributed to the article and approved
the submitted version.
FUNDING
Initial funding for this study was provided by a grant of
the Jose Carreras Leukemia Foundation (DJCLS 01 FN/2018).
This work was supported by the European Cooperation in
Science & Technology under the COST Action CA17138
(Integrated European Network on Chronic Graft vs. Host
Disease: EUROGRAFT) (https://www.gvhd.eu). Infrastructure
support was provided by the University of Regensburg and the
University Hospital Regensburg.
ACKNOWLEDGMENTS
We thank the survivors and partners who participated in this
study for their time and efforts. We also acknowledge the support
provided by the clinic staff, particularly by the members of
the Brückenpflege.
SUPPLEMENTARY MATERIAL




1. Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’
Hematopoietic Cell Transplantation. 4th ed. New York, NY: John Wiley &
Sons (2011).
2. Deutscher Ärzteverlag GmbH, Ärzteblatt RD. Richtlinie: Hämatopoetische
Stammzelltransplantation. (2014). Available from: https://www.aerzteblatt.
de/archiv/161332/Richtlinie-Haematopoetische-Stammzelltransplantation
(accessed December 9, 2019).
3. Müller LP, Müller-Tidow C. The indications for allogeneic stem cell
transplantation in myeloid malignancies. Dtsch Arztebl Int. (2015) 112:262–
70. doi: 10.3238/arztebl.2015.0262
4. Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte
R, et al. The EBMT activity survey on hematopoietic-cell transplantation and
cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant.
(2020) 55:1604–13. doi: 10.1038/s41409-020-0826-4
5. Mosesso K. Adverse late and long-term treatment effects in adult allogeneic
hematopoietic stem cell transplant survivors. Am J Nurs. (2015) 115:22–34;
quiz 35. doi: 10.1097/01.NAJ.0000473311.79453.64
6. Mohty B, Mohty M. Long-term complications and side effects after allogeneic
hematopoietic stem cell transplantation: an update. Blood Cancer J. (2011)
1:e16. doi: 10.1038/bcj.2011.14
7. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious
complications after allogeneic hematopoietic stem cell transplantation. J Infect
Chemother. (2016) 22:505–14. doi: 10.1016/j.jiac.2016.05.006
8. Barata A, Wood WA, Choi SW, Jim HSL. Unmet needs for psychosocial care
in hematologic malignancies and hematopoietic cell transplant. Curr Hematol
Malig Rep. (2016) 11:280–7. doi: 10.1007/s11899-016-0328-z
9. Boyes AW, Girgis A, D’Este C, Zucca AC. Flourishing or floundering?
Prevalence and correlates of anxiety and depression among a population-
based sample of adult cancer survivors 6months after diagnosis. J Affect
Disord. (2011) 135:184–92. doi: 10.1016/j.jad.2011.07.016
10. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol
Blood Marrow Transplant. (2003) 9:215–33. doi: 10.1053/bbmt.2003.50026
11. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet.
(2009) 373:1550–61. doi: 10.1016/S0140-6736(09)60237-3
12. Passweg JR, Baldomero H. Overview: transplant data and increasing
numbers of long-term survivors. In: Savani BN, editor. Blood and Marrow
Frontiers in Public Health | www.frontiersin.org 12 July 2021 | Volume 9 | Article 687675
Parisek et al. GVHD Impacts Life
Transplantation Long Term Management, Prevention and Complications. Vol.
354. Chichester, West Sussex: John Wiley & Sons (2014). p. 7–10.
13. Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition:
the essential need for long-term follow-up clinic for blood and marrow
transplantation survivors. Biol Blood Marrow Transplant. (2015) 21:225–
32. doi: 10.1016/j.bbmt.2014.06.035
14. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. (2006)
354:1813–26. doi: 10.1056/NEJMra052638
15. Raphael D, Frey R, Gott M. The nature and timing of distress among
post-treatment haematological cancer survivors. Eur J Cancer Care. (2019)
28:e12951. doi: 10.1111/ecc.12951
16. Hall A, Campbell HS, Sanson-Fisher R, Lynagh M, D’Este C, Burkhalter
R, et al. Unmet needs of Australian and Canadian haematological cancer
survivors: a cross-sectional international comparative study. Psychooncology.
(2013) 22:2032–8. doi: 10.1002/pon.3247
17. Harrison JD, Young JM, Price MA, Butow PN, Solomon MJ. What are the
unmet supportive care needs of people with cancer? A systematic review.
Support Care Cancer. (2009) 17:1117–28. doi: 10.1007/s00520-009-0615-5
18. Laidsaar-Powell R, Konings S, Rankin N, Koczwara B, Kemp E, Mazariego
C, et al. A meta-review of qualitative research on adult cancer survivors:
current strengths and evidence gaps. J Cancer Surviv. (2019) 13:852–
89. doi: 10.1007/s11764-019-00803-8
19. Hwang JP, Roundtree AK, Giralt SA, Suarez-Almazor M. Late
effects and healthcare needs of survivors of allogeneic stem cell
transplantation: a qualitative study. BMJ Support Palliat Care. (2012)
2:344–50. doi: 10.1136/bmjspcare-2012-000277
20. Bishop MM, Beaumont JL, Hahn EA, Cella D, Andrykowski MA, Brady MJ,
et al. Late effects of cancer and hematopoietic stem-cell transplantation on
spouses or partners compared with survivors and survivor-matched controls.
J Clin Oncol. (2007) 25:1403–11. doi: 10.1200/JCO.2006.07.5705
21. Langer SL, Porter LS, Romano JM, Todd MW, Lee SJ. A couple-
based communication intervention for hematopoietic cell transplantation
survivors and their caregiving partners: feasibility, acceptability, and change
in process measures. Biol Blood Marrow Transplant. (2018) 24:1888–
95. doi: 10.1016/j.bbmt.2018.05.013
22. Siminoff LA. Incorporating patient and family preferences into
evidence-based medicine. BMC Med Inform Decis Mak. (2013)
13(Suppl.):3S6. doi: 10.1186/1472-6947-13-S3-S6
23. Stiggelbout AM, Jansen SJT, Otten W, Baas-Thijssen MCM, van Slooten
H, van de Velde CJH. How important is the opinion of significant
others to cancer patients’ adjuvant chemotherapy decision-making?
Support Care Cancer. (2007) 15:319–25. doi: 10.1007/s00520-006-
0149-z
24. Herrmann A, Sanson-Fisher R, Hall A, Wall L, Zdenkowski N, Waller A.
Support persons’ preferences for the type of consultation and the format of
information provided when making a cancer treatment decision. BMC Res
Notes. (2018) 11:456. doi: 10.1186/s13104-018-3552-x
25. Pulvirenti M, McMillan J, Lawn S. Empowerment, patient
centred care and self-management. Health Expect. (2014)
17:303–10. doi: 10.1111/j.1369-7625.2011.00757.x
26. Jaensch D, Baker N, Gordon S. Contemporaneous patient and health
professional views of patient-centred care: a systematic review. Int J Qual
Health Care. (2019) 31:G165–73. doi: 10.1093/intqhc/mzz118
27. Langer S, Lehane C, Yi J. Patient and caregiver adjustment to hematopoietic
stem cell transplantation: a systematic review of dyad-based studies. Curr
Hematol Malig Rep. (2017) 12:324–34. doi: 10.1007/s11899-017-0391-0
28. Poloméni A, Lapusan S, Bompoint C, Rubio MT, Mohty M. The impact
of allogeneic-hematopoietic stem cell transplantation on patients’ and close
relatives’ quality of life and relationships. Eur J Oncol Nurs. (2016) 21:248–
56. doi: 10.1016/j.ejon.2015.10.011
29. Brice L, Gilroy N, Dyer G, Kabir M, Greenwood M, Larsen S, et al.
Haematopoietic stem cell transplantation survivorship and quality of life:
is it a small world after all? Support Care Cancer. (2017) 25:421–
7. doi: 10.1007/s00520-016-3418-5
30. Lindman A, Krintel Petersen A, Olesen G, Handberg C. Patients’ experiences
and perspectives of challenges and needs related to nonmyeloablative stem
cell transplantation: involving patients in developing a targeted rehabilitation
programme. J Clin Nurs. (2019) 28:1260–72. doi: 10.1111/jocn.14739
31. Holloway I. Qualitative Research in Nursing and Healthcare. Chichester, West
Sussex; Ames, IW: John Wiley et Sons Inc. (2017). 360 p.
32. Kusaka K, Inoguchi H, Nakahara R, Kurosawa S, Fukuda T, Satomura K,
et al. Stress and coping strategies among allogeneic haematopoietic stem
cell transplantation survivors: a qualitative study. Eur J Cancer Care. (2020)
29:e13307. doi: 10.1111/ecc.13307
33. Biagioli V, PireddaM, Alvaro R, deMarinis MG. The experiences of protective
isolation in patients undergoing bone marrow or haematopoietic stem cell
transplantation: systematic review and metasynthesis. Eur J Cancer Care.
(2017) 26. doi: 10.1111/ecc.12461
34. Amonoo HL, Brown LA, Scheu CF, Harnedy LE, Pirl WF, El-Jawahri
A, et al. Beyond depression, anxiety and post-traumatic stress disorder
symptoms: qualitative study of negative emotional experiences in
hematopoietic stem cell transplant patients. Eur J Cancer Care. (2020)
29:e13263. doi: 10.1111/ecc.13263
35. Jepsen LØ, Friis LS, Hoybye MT, Marcher CW, Hansen DG. Rehabilitation
during intensive treatment of acute leukaemia including allogenic stem cell
transplantation: a qualitative study of patient experiences. BMJ Open. (2019)
9:e029470. doi: 10.1136/bmjopen-2019-029470
36. Leppla L, Mielke J, Kunze M, Mauthner O, Teynor A, Valenta S, et al.
Clinicians and patients perspectives on follow-up care and eHealth support
after allogeneic hematopoietic stem cell transplantation: a mixed-methods
contextual analysis as part of the SMILe study. Eur J Oncol Nurs.
(2020) 45:101723. doi: 10.1016/j.ejon.2020.101723
37. Morrison CF, Pai ALH, Martsolf D. Facilitators and barriers to self-
management for adolescents and young adults following a hematopoietic
stem cell transplant formula: see text. J Pediatr Oncol Nurs. (2018) 35:36–
42. doi: 10.1177/1043454217723864
38. Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg
HJ, et al. Life expectancy in patients surviving more than 5 years
after hematopoietic cell transplantation. J Clin Oncol. (2010) 28:1011–
6. doi: 10.1200/JCO.2009.25.6693
39. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley
JF, et al. Health and functional status of long-term survivors
of bone marrow transplantation. EBMT Working Party on Late
Effects and EULEP Study Group on Late Effects. European Group
for Blood and Marrow Transplantation. Ann Intern Med. (1997)
126:184–92. doi: 10.7326/0003-4819-126-3-199702010-00002
40. Chen Y-Y, Wang C-C, WuW-T, Lai C-H, Ho C-L, Hsu Y-Y, et al. Trajectories
of returning to work and its impact on survival in survivors with oral cancer: a
5-year follow-up study. Cancer. (2020) 126:1225–34. doi: 10.1002/cncr.32643
41. Yu Y, Carey M, Pollett W, Green J, Dicks E, Parfrey P, et al. The long-term
survival characteristics of a cohort of colorectal cancer patients and baseline
variables associated with survival outcomes with or without time-varying
effects. BMCMed. (2019) 17:150. doi: 10.1186/s12916-019-1379-5
42. Glaser BG, Strauss AL. Grounded Theory: STRATEGIEN Qualitativer
Forschung. 3rd ed. Bern: Verlag Hans Huber (2010). 278 p.
43. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K.
Purposeful sampling for qualitative data collection and analysis in mixed
method implementation research. Adm Policy Ment Health. (2015) 42:533–
44. doi: 10.1007/s10488-013-0528-y
44. Fitch MI. Supportive care framework. CONJ. (2008) 18:6–
14. doi: 10.5737/1181912x181614
45. Woods P, Gapp R, King MA. Generating or developing grounded theory:
methods to understand health and illness. Int J Clin Pharm. (2016) 38:663–
70. doi: 10.1007/s11096-016-0260-2
46. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the
framework method for the analysis of qualitative data in multi-
disciplinary health research. BMC Med Res Methodol. (2013)
13:13117. doi: 10.1186/1471-2288-13-117
47. Flick U, Kardorff E von, Steinke I, editors. Qualitative Forschung: Ein
Handbuch. 12th ed. In: Rororo Rowohlts Enzyklopädie. vol. 55628. Reinbek
bei Hamburg: rowohlts enzyklopädie im Rowohlt Taschenbuch Verlag (2017).
767 p.
48. Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications,
decreasing re-hospitalizations, and reducing cost burden in long-term
survivors after allogeneic hematopoietic stem cell transplantation. Semin
Hematol. (2012) 49:10–4. doi: 10.1053/j.seminhematol.2011.10.009
Frontiers in Public Health | www.frontiersin.org 13 July 2021 | Volume 9 | Article 687675
Parisek et al. GVHD Impacts Life
49. Scherwath A, Schirmer L, KruseM, Ernst G, EderM, Dinkel A, et al. Cognitive
functioning in allogeneic hematopoietic stem cell transplantation recipients
and its medical correlates: a prospective multicenter study. Psychooncology.
(2013) 22:1509–16. doi: 10.1002/pon.3159
50. Jim HSL, Quinn GP, Gwede CK, Cases MG, Barata A, Cessna J, et al.
Patient education in allogeneic hematopoietic cell transplant: what patients
wish they had known about quality of life. Bone Marrow Transplant. (2014)
49:299–303. doi: 10.1038/bmt.2013.158
51. Duarte-Climents G, Sánchez-Gómez MB, Rodríguez-Gómez JÁ, Rodríguez-
Álvarez C, Sierra-López A, Aguirre-Jaime A, et al. Impact of the case
management model through community liaison nurses. Int J Environ Res
Public Health. (2019) 16. doi: 10.3390/ijerph16111894
52. Aued GK, Bernardino E, Lapierre J, Dallaire C. Atividades das enfermeiras
de ligação na alta hospitalar: uma estratégia para a continuidade do
cuidado [Liaison nurse activities at hospital discharge: a strategy
for continuity of care]. Rev Lat Am Enfermagem. (2019) 27:e3162.
por. doi: 10.1590/1518-8345.3069.3162
53. Rice RD, Bailey G. Management issues in hematopoietic
stem cell transplantation. Semin Oncol Nurs. (2009) 25:151–
8. doi: 10.1016/j.soncn.2009.03.009
54. Muhsen IN, Bar M, Savani BN, Estey EH, Hashmi SK. Follow-up issues
in survivors of hematologic malignancies - Current stance and future
perspectives. Blood Rev. (2020) 44:100674. doi: 10.1016/j.blre.2020.100674
55. McConnell H, White R, Maher J. Categorising cancers to enable tailored care
planning through a secondary analysis of cancer registration data in the UK.
BMJ Open. (2017) 7:e016797. doi: 10.1136/bmjopen-2017-016797
56. Wagner EH, Bennett SM, Austin BT, Greene SM, Schaefer JK, Vonkorff
M. Finding common ground: patient-centeredness and evidence-
based chronic illness care. J Altern Complement Med. (2005) 11:S7–15.
doi: 10.1089/acm.2005.11.s-7
57. John JR, Jani H, Peters K, Agho K, Tannous WK. The effectiveness of patient-
centred medical home-based models of care versus standard primary care
in chronic disease management: a systematic review and meta-analysis of
randomised and non-randomised controlled trials. Int J Environ Res Public
Health. (2020) 17. doi: 10.3390/ijerph17186886
58. Fertel BS, Podolsky SR, Mark J, Muir MR, Ladd ME, Smalley CM. Impact of
an individual plan of care for frequent and high utilizers in a large healthcare
system. Am J Emerg Med. (2019) 37:2039–42. doi: 10.1016/j.ajem.2019.02.032
59. Majhail NS, Murphy E, Laud P, Preussler JM, Denzen EM, Abetti B,
et al. Randomized controlled trial of individualized treatment summary
and survivorship care plans for hematopoietic cell transplantation survivors.
Haematologica. (2019) 104:1084–92. doi: 10.3324/haematol.2018.203919
60. Jansen DL, Heijmans M, Rijken M. Individual care plans for
chronically ill patients within primary care in the Netherlands:
dissemination and associations with patient characteristics and
patient-perceived quality of care. Scand J Prim Health Care. (2015)
33:100–6. doi: 10.3109/02813432.2015.1030167
61. Rijken M, van der Heide I, Heijmans M. Individual care plans in
chronic illness care: aims, use and outcomes. Int J Integr Care. (2016)
16:209. doi: 10.5334/ijic.2757
62. Günther B. Achtsame Kommunikation in der Arztpraxis: Technik, Kultur,
Führung und Selbstmanagement. Berlin:MWVMedizinischWissenschaftliche
Verlagsges. mbH & Co. KG. (2015). 94 p.
63. Laitinen H, Kaunonen M, Åstedt-Kurki P. The impact of using electronic
patient records on practices of reading and writing. Health Informatics J.
(2014) 20:235–49. doi: 10.1177/1460458213492445
64. Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, et al.
Postdischarge communication between home health nurses and physicians:
measurement, quality, and outcomes. J Am Geriatr Soc. (2015) 63:1299–
305. doi: 10.1111/jgs.13491
65. Williams C, Hamadi H, Cummings C, Zakari NMA. Information processing
in electronic medical records: a survey validation. J Eval Clin Pract. (2019)
25:97–103. doi: 10.1111/jep.13017
66. Bush ML, Kaufman MR, Shackleford T. Adherence in the cancer care setting:
a systematic review of patient navigation to traverse barriers. J Cancer Educ.
(2018) 33:1222–9. doi: 10.1007/s13187-017-1235-2
67. Jabson JM. Treatment summaries, follow-up care instructions, and
patient navigation: could they be combined to improve cancer
survivor’s receipt of follow-up care? J Cancer Surviv. (2015)
9:692–8. doi: 10.1007/s11764-015-0444-0
68. Berezowska A, Passchier E, Bleiker E. Evaluating a professional patient
navigation intervention in a supportive care setting. Support Care Cancer.
(2019) 27:3281–90. doi: 10.1007/s00520-018-4622-2
69. Maher M, Kaziunas E, Ackerman M, Derry H, Forringer R, Miller K,
et al. User-Centered design groups to engage patients and caregivers with
a personalized health information technology tool. Biol Blood Marrow
Transplant. (2016) 22:349–58. doi: 10.1016/j.bbmt.2015.08.032
70. Chaar D, Shin JY, Mazzoli A, Vue R, Kedroske J, Chappell G, et al. A mobile
health app (Roadmap 2.0) for patients undergoing hematopoietic stem cell
transplant: qualitative study on family caregivers’ perspectives and design
considerations. JMIR Mhealth Uhealth. (2019) 7:e15775. doi: 10.2196/15775
71. Racioppi A, Dalton T, Ramalingam S, Romero K, Ren Y, Bohannon L,
et al. Assessing the feasibility of a novel mhealth app in hematopoietic
stem cell transplant patients. Transplant Cell Therapy. (2021)
27:181.e1. doi: 10.1016/j.jtct.2020.10.017
72. Leppla L, Hobelsberger S, Rockstein D, Werlitz V, Pschenitza S, Heidegger
P, et al. Implementation science meets software development to create
ehealth components for an integrated care model for allogeneic stem cell
transplantation facilitated by eHealth: The SMILe Study as an example. J Nurs
Scholarsh. (2021) 53:35–45. doi: 10.1111/jnu.12621
73. Visser L.How oncologists’ Communication Impacts Patients’ Information Recall
and Emotional Stress. A Video-Vignettes Approach. Ridderkerk: Ridderprint
(2017).
74. Dang BN, Westbrook RA, Njue SM, Giordano TP. Building trust and rapport
early in the new doctor-patient relationship: a longitudinal qualitative study.
BMCMed Educ. (2017) 17:32. doi: 10.1186/s12909-017-0868-5
75. Charles C, Gafni A, Whelan T. Decision-making in the physician–patient
encounter: revisiting the shared treatment decision-making model. Soc Sci
Med. (1999) 49:651–61. doi: 10.1016/S0277-9536(99)00145-8
76. Montori VM, Gafni A, Charles C. A shared treatment decision-
making approach between patients with chronic conditions
and their clinicians: the case of diabetes. Health Expect. (2006)
9:25–36. doi: 10.1111/j.1369-7625.2006.00359.x
77. Kambhampati S, Ashvetiya T, Stone NJ, Blumenthal RS, Martin SS. Shared
decision-making and patient empowerment in preventive cardiology. Curr
Cardiol Rep. (2016) 18:49. doi: 10.1007/s11886-016-0729-6
78. Back AL, Fromme EK, Meier DE. Training clinicians with communication
skills needed to match medical treatments to patient values. J Am Geriatr Soc.
(2019) 67:S435–41. doi: 10.1111/jgs.15709
79. O’Hara LM, Caturegli I, O’Hara NN, O’Toole RV, Dalury DF, Harris AD, et al.
What publicly available quality metrics do hip and knee arthroplasty patients
care about most when selecting a hospital in Maryland: a discrete choice
experiment. BMJ Open. (2019) 9:e028202. doi: 10.1136/bmjopen-2018-028202
80. Hibbard JH, Stockard J, Tusler M. Does publicizing hospital
performance stimulate quality improvement efforts? Health Aff. (2003)
22:84–94. doi: 10.1377/hlthaff.22.2.84
81. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical
institutions: what is it, can it be measured, and does it matter? Milbank Q.
(2001) 79:613–39. doi: 10.1111/1468-0009.00223
82. Charles C, Gafni A, Whelan T. Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med
(1982). (1997) 44:681–92. doi: 10.1016/S0277-9536(96)-3
83. Moxley DP. The Practice of Case Management. 10th ed. Newbury Park: Sage
Publ (1996). 157 p.
84. Gerteis M. Through the Patient’s Eyes: Understanding and Promoting Patient-
Centered Care. San Francisco, CA: Jossey-Bass (1993). Xxvii p.
85. Ah DV, Spath M, Nielsen A, Fife B. The caregiver’s role across the
bone marrow transplantation trajectory. Cancer Nurs. (2016) 39:E12–
9. doi: 10.1097/NCC.0000000000000242
86. Foster LW, McLellan L, Rybicki L, Dabney J, Copelan E, Bolwell B. Validating
the positive impact of in-hospital lay care-partner support on patient survival
in allogeneic BMT: a prospective study. Bone Marrow Transplant. (2013)
48:671–7. doi: 10.1038/bmt.2012.208
87. Foster LW, McLellan LJ, Rybicki LA, Sassano DA, Hsu A, Bolwell BJ. Survival
of patients who have undergone allogeneic bone marrow transplantation. J
Psychosoc Oncol. (2005) 22:1–20. doi: 10.1300/J077v22n02_01
Frontiers in Public Health | www.frontiersin.org 14 July 2021 | Volume 9 | Article 687675
Parisek et al. GVHD Impacts Life
88. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A,
et al. Lack of caregivers limits use of outpatient hematopoietic
stem cell transplant program. Bone Marrow Transplant. (2002)
30:741–8. doi: 10.1038/sj.bmt.1703676
89. Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J.
Effects of aerobic exercise on the physical performance and
incidence of treatment-related complications after high-dose
chemotherapy. Blood. (1997) 90:3390–4. doi: 10.1182/blood.V90.
9.3390
90. Abo S, Ritchie D, Denehy L, Panek-Hudson Y, Irving L, Granger CL. A
hospital and home-based exercise program to address functional decline in
people following allogeneic stem cell transplantation. Support Care Cancer.
(2018) 26:1727–36. doi: 10.1007/s00520-017-4016-x
91. Wiskemann J, Kleindienst N, Kuehl R, Dreger P, Schwerdtfeger R, Bohus
M. Effects of physical exercise on survival after allogeneic stem cell
transplantation. Int J Cancer. (2015) 137:2749–56. doi: 10.1002/ijc.29
633
92. Stewart M. Towards a global definition of patient centred care. BMJ. (2001)
322:444–5. doi: 10.1136/bmj.322.7284.444
93. Bjørnholt M, Farstad GR. ‘Am I rambling?’ on the advantages of interviewing
couples together. Qual Res. (2014) 14:3–19. doi: 10.1177/1468794112459671
94. Allan G. A note on interviewing spouses together. J Marriage Fam. (1980)
42:205. doi: 10.2307/351948
95. Taylor B, de Vocht H. Interviewing separately or as couples?
Considerations of authenticity of method. Qual Health Res. (2011)
21:1576–87. doi: 10.1177/1049732311415288
Conflict of Interest: HS has received financial compensation for advisory
boards (Incyte, Janssen, and Novartis), speaker’s fees [Novartis, Incyte, Jazz
Pharmaceuticals, the Belgian Hematological Society (BHS) and Takeda], travel
grants (AbbVie, Celgene, CIBMTR, EBMT, Gilead, and Incyte), and research
funding (Novartis and the BHS). She also frequently served as a volunteer for the
BHS, the CIBMTR, EBMT, and EUPATI. DWo received honoraria from Novartis,
Behring, Mallinckrodt, MACO, and Incyte.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Parisek, Loss, Holler, Barata, Weber, Edinger, Wolff, Schoemans
and Herrmann. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Public Health | www.frontiersin.org 15 July 2021 | Volume 9 | Article 687675
